Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese CRO EPS To Develop And Market Drugs In China

This article was originally published in PharmAsia News

Executive Summary

Japanese CRO EPS has entered the drug development business in China. The company has signed an agreement with Japanese mid-sized drug companies to market two drugs in China. Chinese clinical trials will be starting this year and the company aims for approvals by March 2010. EPS also plans to license five more drugs to market in China, and invest ¥100-¥200 million to start the clinical trials. EPS entered China in 1999, and the company has since established a Beijing EPS subsidiary to support new drug development. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072075

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel